aXichem's CEO Torsten Helsing is interviewed "live" from Expo West 2023

10 March 2023 - 13:30

In conjunction with aXichem's ongoing rights issue, CEO Torsten Helsing has been interviewed by Per Lönn, Västra Hamnen Corporate Finance. Torsten Helsing is participating at Expo West 2023 in the Anaheim Convention Center in California, USA, March 7-11, and has this past week presented the company's innovative natural analog phenylcapsaicin product aXivite® together with partner SEE Nutrition.

See the interview (in Swedish only) here:

More information about aXichem's rights issue

One (1) existing share gives one (1) subscription right. Seven (7) subscription rights give the right to subscribe for three (3) newly issued shares.

The subscription price per share amounts to SEK 7.00. The total issue amount amounts to SEK 49.6 million, before issue costs.

The prospectus, which contains complete conditions and instructions, is available on the aXichem’s, Nordic Issuing AB's and Västra Hamnen Corporate Finance AB's respective websites (,, The prospectus is also available on the Finansinspektionen's website (

Presentations for investors

On Tuesday, March 14, 2023 at 4:00 p.m., the Company's CEO, Torsten Helsing, will give a presentation at Aktiespararna's event “Stora Aktiedagarna” in Stockholm. Questions to the company can be sent to Aktiespararna before the event and registration can be sent via the following link:

In addition, Västra Hamnen Corporate Finance invites you to a webcast company presentation with CEO Torsten Helsing on Thursday, March 16, 2023 at 2:00 p.m. After the presentation, the audience is given the opportunity to ask questions. Questions can also be asked in advance to [email protected] The presentation is held in Swedish and can be followed via computer or mobile devices. Registration for the web conference is done via the following link:

Financial advisers, legal advisers and issuing institutes

Västra Hamnen Corporate Finance AB (publ) acts as financial advisor and Vinge is legal advisor to aXichem in connection with the Rights Issue. Nordic Issuing acts as an issuing institution.

The information was submitted, through the care of the contact person, for publication on 10 March 2023, at 13:30 CEST.

Torsten Helsing, CEO, aXichem, Ph+46 70 686 33 55. Email: [email protected]

aXichem’s business idea is to develop, patent and market natural analogue industrial compounds. The Company primarily works with phenylcapsaicin a structural analogue of capsaicin with a wide range of applications, such as feed additives, nutraceuticals and certain pharmaceutical areas. aXichem’s shares are listed on NASDAQ First North Growth Market under AXIC A. Certified Adviser: Västra Hamnen Corporate Finance, Read more about aXichem at 

Provided by: Cision
Nasdaq First North GM Stockholm (Sweden)
aXichem AB
aXichem develops and delivers nature-identical ingredients of the highest purity. The Company offers axiphen-feed used in the breeding of chicken and pigs, Bio-repellents used to repel unwanted biological organisms from installations or areas and aXivite an alternative to capsaicin....
Learn more about company

Related news

We use cookies to make your experience using IPOhub better. By using our site you agree to our use of cookies. Learn More